Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
暂无分享,去创建一个
G. Botti | N. Normanno | F. Fenizia | F. Ciardiello | G. Colucci | E. Maiello | G. Tonini | T. Troiani | E. Martinelli | F. Tatangelo | A. Rinaldi | F. Giuliani | C. Barone | M. Orditura | G. Cartenì | V. Montesarchio | S. Cinieri | F. De Vita | S. Pisconti | R. Bordonaro | A. Rachiglio | M. Lambiase | A. Febbraro | D. Rizzi | F. Vita | Erika Martinelli | Francesco Giuliani | Fortunato Ciardiello | Giacomo Cartenì | Nicola Normanno | Giuseppe Colucci | Fabiana Tatangelo | Giovanni Botti | Vincenzo Montesarchio
[1] W. Scheithauer,et al. Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. , 2014 .
[2] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.
[3] G. Fasola,et al. Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). , 2013 .
[4] B. Tops,et al. Abstract 36: The OncoNetwork Consortium: A European Collaborative Research study on the development of an Ion AmpliSeq gene panel targeting hot spots in colon and lung cancers. , 2013 .
[5] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[6] A. Marchetti,et al. KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment , 2011, PloS one.
[7] Sabine Tejpar,et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. , 2011, The Lancet. Oncology.
[8] Renzo Boldorini,et al. Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer , 2011, Clinical Cancer Research.
[9] E. Van Cutsem,et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. Laurent-Puig,et al. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. , 2011, The oncologist.
[11] Josep Tabernero,et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[13] F. J. Ramos,et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[15] L. Mazzucchelli,et al. Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer , 2009, PloS one.
[16] Sabine Tejpar,et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC , 2009, Nature Reviews Clinical Oncology.
[17] G. Tortora,et al. EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.